Local News

Blaze Bioscience Gets Fast Track Approval from FDA for ‘Tumor Paint’ That Helps Remove Brain Tumors

By April 9, 2020No Comments

Seattle biotech company Blaze Bioscience has received Fast Track designation from the FDA for a clinical program evaluating tozuleristide.

  • Also known as BLZ-100, tozuleristide is what the company refers to as “Tumor Paint,” a molecule that binds to cancer cells and lights them up to help brain surgeons remove tumors.
  • Tumor Paint was created using a peptide, or a small protein, from the Israeli deathstalker scorpion. But the formula is entirely synthetic. It is currently being evaluated in a phase 2/3 clinical trial with pediatric patients.
  • The Fast Track designation expedites the approval process for bringing drugs to market. “Pediatric brain tumors remain the leading cause of cancer-related death among children and adolescents,” Dr. Dennis Miller, Blaze Bioscience executive vice president of development, said in a statement. “We look forward to our continued collaborative relationship with FDA as we work to complete the clinical and other product development work needed to speed the product to approval.”